The Endocrinology and Metabolism Professional Committee of the National Association of Health Industry and Enterprise Management produced a 2026 expert consensus updating clinical recommendations on hypoglycemic agents that act on nutrient‑stimulated hormone (NuSH) receptors for the treatment of type 2 diabetes mellitus (T2DM). This update builds on a 2020 consensus focused on glucagon‑like peptide‑1 receptor agonists and incorporates newly accumulated evidence and recently developed agents.
The consensus addresses three classes of NuSH receptor‑targeting agents: GLP‑1 receptor agonists, dual GIP/GLP‑1 receptor agonists, and dual glucagon/GLP‑1 receptor agonists. The PubMed abstract identifies these mechanisms as the focus but does not list individual drug names or dosing regimens; those details are available in the full text link provided by the publisher.
According to the abstract, NuSH receptor agonists confer multiple metabolic benefits in addition to lowering blood glucose. Reported effects include weight reduction, blood pressure lowering, improvement in lipid profiles, and attenuation of hepatic steatosis. The consensus emphasizes that these broader metabolic effects contribute to the therapeutic value of the drug class in managing patients with T2DM.
The abstract specifically notes that NuSH receptor agonists have demonstrated cardiovascular and renal benefits. The consensus update incorporated evidence on these organ‑level outcomes when formulating recommendations. Specific trial data, effect sizes, or subgroup analyses are not provided in the PubMed abstract and would need to be consulted in the full article for granular guidance.
The committee conducted a literature search of recent publications and evaluated the evidence base to inform the update. Endocrinology specialists convened for multiple rounds of rigorous deliberation and iterative revision. This structured process resulted in an updated consensus that reflects newly available evidence since the 2020 guidance.
The consensus concentrates on several practical clinical questions:
The PubMed abstract indicates that the committee’s deliberations produced recommendations across these domains, but the abstract itself does not present the detailed recommendations.
The updated consensus formulates 10 recommended opinions intended to guide clinicians in the standardized use of NuSH receptor agonists for T2DM. The PubMed record reports the number and general themes of these recommendations but does not reproduce their full text or enumerated content. To implement the specific recommendations in clinical practice, clinicians should consult the full consensus document via the publisher link.
The PubMed entry states that all authors declared no conflicts of interest. The citation details are Zhonghua Yi Xue Za Zhi. 2026 Aug 25;106(31):3222–3233, PMID 42618499, DOI 10.3760/cma.j.cn112137-20260527-01398. An English abstract is available in the PubMed record; the full text is linked through the Chinese Medical Association Publishing House Ltd.
Clinicians should recognize that NuSH receptor agonists are positioned not only for glycemic control but also for weight reduction and potential cardiorenal and hepatic benefits in T2DM management. The 2026 consensus updates prior guidance and offers 10 recommendations to help determine when to start these agents, how to combine them with other therapies, and how to consider organ‑level outcomes. Specific dosing, patient selection criteria, contraindications, monitoring, and management of adverse effects are likely detailed in the full text and should be reviewed before changing practice.
The information summarized here derives from the PubMed abstract, which outlines scope, themes and the existence of 10 recommendations but does not provide the full recommendation text, supporting evidence tables, or practical algorithms. For complete guidance, clinicians should access the full consensus statement via the provided full text link (Chinese Medical Association Publishing House Ltd.) or consult the DOI record. The PubMed entry includes MeSH terms and indexing that confirm the focus on T2DM pharmacotherapy and GLP‑1 receptor agonists.